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Abstract  
Background: The incidence of retinopathy of prematurity (ROP) and ROP screening criteria 
differ between countries. We assessed whether ROP screening could be reduced based on the 
local ROP incidence.  
Methods: Observational cohort study of infants born in Switzerland between 2006 and 2015 
<32 0/7 weeks. Chronological and postmenstrual ages at ROP treatment were analyzed. A 
model to identify ROP treatment on patients born 2006-2012 (training set) was developed and 
tested on patients born 2013-2015 (validation set).  
Results:  Of 7817 live-born infants, 1098 died within the first five weeks of life. The 
remaining 6719 infants were included into analysis. All patients requiring ROP treatment 
would have been identified if screening had been performed before reaching 60 days of life or 
37 3/7 weeks postmenstrual age, whichever came first.  
The training and validation sets included 4522 and 2197 preterm infants encompassing 56 and 
20 patients receiving ROP treatment, respectively. All patients would have required screening 
to reach 100% sensitivity. To reach a sensitivity of 95.0% and a specificity of 87.6% we 
predicted a reduction to 13.2% of patients requiring screening (c-statistic = 0.916).  
Conclusions: A substantial reduction of infants requiring screening seems possible but 
necessitates prospective testing of new screening criteria.  
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Introduction 
Retinopathy of prematurity (ROP) is a severe complication of preterm birth and may lead to 
severe visual impairment or even blindness. It is a two stage developmental vascular 
proliferative disorder resulting from a mismatch between oxygen demand and oxygen supply 
within the retina (1, 2). By now a large variety of risk factors for the development of ROP 
have been described, but it is not clear which risk factors are truly independent and which 
factors are rather associations (3). 
In developed countries the incidence of ROP in preterm infants below 28 weeks of gestational 
age (GA) ranges widely between 25 and 91%, with treatment rates varying between 2% and 
30% (4). Criteria for ROP screening differ between countries and, in developed countries, 
usually include patients below 31-32 weeks of gestational age (GA) and a birthweight (BW) 
below 1250-1500g. All recommendations extend ROP screening to patients above given 
limits for gestational age and birth weight if additional risk factors were present. These factors 
are not clearly defined but include prolonged oxygen therapy (Argentina(5)), respiratory 
problems or sepsis (Brazil (6)), “infants believed to be at high risk for ROP” (Canada (7)), or 
“unstable clinical course with cardiorespiratory support and are believed to be at high risk of 
ROP” (USA(8)).  
However, these criteria seem to miss patients potentially requiring treatment in developing 
countries (9, 10). Screening inclusion criteria for ROP need to reach a high sensitivity to 
avoid missing patients that potentially could suffer severe consequences such as blindness. 
When prevalence is small, high sensitivity leads to low specificity with many patients 
screened that ultimately do not require treatment. The lower the prevalence for infants 
requiring ROP treatment, the more crucial it is to optimize screening criteria in order to 
reduce work load in the NICUs, financial expenses and, most importantly, avoidable stress for 
preterm infants. This is an issue in particular in Switzerland with its very low prevalence of 
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ROP treatment with 4.3% compared to other countries like Canada (10.4%), United Kingdom 
(8.5%) or Australia & New Zealand with 7.3%  in preterm infants below 28 weeks (4, 11). 
The aim of this study was to assess if screening criteria for ROP can be optimized in very low 
birth weight (VLBW, birth weight below 1500g) infants in Switzerland. All VLBW infants 
live-born between 2006 and 2015 in Switzerland were included in this study.  
 
 
 
Patients and Methods 
 
This study is based on a retrospective analysis of patients who were born between 2006 and 
2015 and were registered at the national registry of very preterm infants in Switzerland 
(SwissNeoNet, SNN) of the Swiss Society of Neonatology. The network prospectively 
collects perinatal and follow-up data of live born infants with a gestational age between 22 0/7 
weeks and less than 32 0/7 weeks or a birth weight of less than 1501g. All 9 Swiss perinatal 
centers, 5 step-down units and 16 neuro-/developmental pediatric units participated. Routine 
comparison with the Swiss Federal Statistical Office reveals 96% population coverage. This 
study includes patients with a gestational age below 32 0/7 weeks and focused on data from 
the perinatal dataset plus the information of any ROP treatment after primary discharge home 
from the 18 to 24 months follow-up assessment. Infants with a gestational age as of 32 0/7 
and a birth weight below 1501g were excluded because a cohort with both gestational age and 
birth weight as cutoff cannot include gestational age as main predictor. None of these infants 
were treated for ROP. We excluded all infants that died before reaching 5 weeks of age as 
they never would have received a ROP screening. 
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Screening criteria for ROP differed slightly between the individual centers. ROP screening 
criteria included a birth weight of <1500g in eight of nine Swiss hospitals with tertiary 
neonatal care. The remaining center screened only patients with a birth weight below 1250g. 
In seven hospitals preterm infants with a gestational age of less than 32 0/7 weeks were 
screened, while in the remaining two centers the cutoff was at 30 0/7 weeks. One center 
started screening at a postnatal age of more than seven weeks; all other centers started ROP 
screening between 4 and 5 weeks. Administration of supplemental oxygen for ≥3 days or 
unstable clinical course was defined as additional screening criterion in most hospitals. The 
final model contained the following 5 risk factors: GA, birth weight z-score, CPAP > 3 days, 
multiple birth and surfactant. The parameters rejected were: male sex, caesarean section, any 
antenatal steroids, delivery room intubation and mean weight gain per week hospital stay, any 
mechanical ventilation, supplemental oxygen > 3 days. The date of first ROP screening 
differed between 6 and 8 weeks postnatally. ROP was assessed by indirect ophthalmoscopy 
by the attending ophthalmologists. In Switzerland, all ROP treatments are performed by one 
of five ophthalmological clinics.  
 
 
Definitions 
Stages of ROP were categorized according to the international classification of retinopathy of 
prematurity (12). Severe ROP (sROP) was defined as ROP stages 3-5. Data on retinal zones 
and development of plus disease were not available from the database. ROP was stratified as 
treated ROP when any form of therapy (laser coagulation or intravitreal anti-VEGF) was 
performed according to current recommendations.  
Patients were classified as small for gestational age (SGA) when the birth weight was below 
the 10
th
 percentile based on the growth curves by Voigt et al. (13). Length of support with 
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supplemental oxygen, CPAP and mechanical ventilation was measured as number of days 
during hospitalization with more than 12 hours of the different form of respiratory support, 
respectively. We defined bronchopulmonary dysplasia (BPD) as an oxygen requirement at 36 
weeks postmenstrual age according to the NICHD consensus conference paper (14), NEC as 
clinical signs (abdominal distension, bilious aspirates and/or bloody stools) confirmed by 
radiographically visible intramural gas or at laparotomy (Bell stages 2 and 3) (15), and 
antenatal steroid use as any administration prior to birth, regardless of the time interval. 
Growth per week was calculated as weight at discharge or death minus weight at birth divided 
by the amount of weeks from birth until first discharge home or until death. Sepsis was 
defined as clear clinical evidence of infection plus at least one positive blood culture 
(including coagulase negative staphylococci and fungal pathogens). Severe intraventricular 
hemorrhage (sIVH) was based on the most severe ultrasound result during hospital stay 
reaching grade 3 to 4 of the classification defined by Papile et al. (16).  
 
Ethics 
Data collection and evaluation for this study were approved by the Swiss Federal Commission 
for Privacy Protection in Medical Research and the Swiss ethical review boards (KEK-ZH-Nr. 
2014-0551 and KEK-ZH-Nr. 2014-0552). The patients’ representatives were informed about 
the use of data for research.  
 
Statistical methods 
Based on risk factors of patients born 2006-2012 (training set), a mathematical model using 
logistic regression for the outcome ROP intervention was performed using a step-wise 
elimination process while ensuring that variable elimination did not significantly change the 
model. An elimination of a variable was accepted only if the model with the variable was not 
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significantly different to the model without the variable according to Wald (p<0.10)(17). The 
final model contained the following 7 risk factors: GA, days of supplemental oxygen, days of 
CPAP, days of mechanical ventilation, birth weight z-score, surfactant, and multiple birth. 
The parameters rejected were: male sex, caesarean section, any antenatal steroids, delivery 
room intubation and mean weight gain per week hospital stay. To test validity of this model to 
predict preterm infants requiring ROP intervention it was applied on patients born 2013-2015 
(validation set). Sensitivity and specificity were analyzed as well as ROC curves and 
predictive c-statistics. Model building and validation was based on five-fold imputed data 
using multivariate imputation by chained equations based on random forest.  
Three of the included parameters are not available at birth: duration of supplemental oxygen, 
CPAP and mechanical ventilation. We included a sensitivity analysis using these parameters 
as categorical data; whether or not they had longer than median length of respiratory support 
(supplemental Oxygen >3 days, CPAP > 3days, mechanical ventilation > 0 days).  
Cochrane-Armitage test for trend was used to test the decrease of mortality over time. Results 
with a p-value of less than 0.05 were considered significant. Analyses were performed with 
SPSS Version 21 (IBM Corporation, Armonk, NY) and R 3.4 (r-project for statistical 
computing; www.r-project.org).  
 
The following prediction model formula was applied:  
 
 
b0 = intercept; bk = maximum likelihood estimate for chosen risk factors,; xk = risk factor 
values of individual patient. 
 
 
p y = 1   x1, … x𝑝 =
exp b0 +  Sum b𝑘 ∗ x𝑘  
1 +  exp b0 +  Sum b𝑘 ∗ x𝑘   
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Results 
Record completeness of all infants according to comparison with Swiss Federal Statistical 
Office was 96%. Of the 7817 patients registered in the SNN database, information on ROP 
treatment was missing for 1116 patients of whom we retrospectively collected and completed 
942 cases, leading to a data completeness of 97.8%. After exclusion of patients who died in 
the delivery room or during the first 5 weeks of life in hospital, 6719 infants remained for 
analyses.    
 
Characteristics of included patients eligible to ROP screening are shown in table 1. Analyses 
showed that the majority of patients requiring ROP therapy were born with a gestational age 
below 28 weeks. ROP was treated in only 13, 6 and 3 patients at a gestational age of ≥27 0/7, 
≥28 0/7 and ≥29 0/7 weeks, respectively (Figure 1). Patient characteristics of these patients 
are shown in table 2. The mortality at five weeks of age, after which ROP screening usually 
begins, significantly declined between 2006 and 2015 (p = 0.03) raising the proportion of 
infants at risk for developing ROP over the years. 
 
Infants were treated for ROP at a GA of 38.17 ± 3.46 weeks, range 32.85 – 56.42 weeks. Only 
two patients were treated with a lower gestational age than 34 0/7 weeks and in three patients 
ROP therapy was performed after 44 weeks GA. The chronological age at ROP treatment was 
88 ± 24 days with a range from 41 to 215 days with one patient being treated before 60 days 
of life. The combination of GA and chronological age showed that all patients would have 
been identified prior to ROP treatment when screening had begun at 60 days of life or a GA 
of 37.42 weeks whichever is reached first.   
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GA-stratified analysis revealed that missing data were randomly distributed for most of the 
parameters. Antenatal steroids had a higher rate of missing data at 23 weeks gestational age 
(17.2%) and 24 weeks (5.4%), respectively, ROP intervention had a higher rate of missing 
data in infants with a gestational age of 31 weeks (5.3%). Logistic regression analysis was 
based on five-fold imputed data to compensate for missing values in antenatal steroids (2.7%), 
ROP intervention (2.6%) and to a minor degree in other parameters. Without data imputation, 
all cases with missing information for either the primary outcome (ROP intervention) or one 
of the predictors would have been eliminated from the model prior to model building. This 
would have led to the higher rate of exclusion of data on either end of the gestational age 
range. 
 
The training set (patients born 2006-2012) had a patient population of 4522 preterm infants 
<32 weeks GA, including 56 patients with treated ROP. The validation set (patients born 
2013-2015) included 2197 patients with 20 ROP therapies. Table 3 shows values, which 
resulted from analyses of our patient characteristics and were included in the final model. 
 
Depending on the cutoff-point, the logistic regression model allows predicting the number of 
false negative cases, i.e. cases for which a ROP intervention was performed during 2013-2015 
but which was not detected by the model. Number of infants needed to test, true positives, 
false negatives, sensitivity and specificity for each cutoff value are displayed in table 4. 
Results show that all patients needed to be screened to reach a sensitivity of 100%. However, 
to reach a sensitivity of 95.0% (one patient false negative) and specificity of 87.6% the model 
predicted a reduction in the number of screened patients to 13.2%. This reflects a high 
predictive c-statistics value of 0.916 (Figure 2). The undetected patient was born at 30+1 
weeks with congenital nephroblastoma and therefore probably with a different 
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pathophysiology than the average patient requiring ROP treatment towards which the 
prediction model was fit.  
The analysis, using supplemental oxygen, duration of CPAP and duration of mechanical 
ventilation as categorical variables showed almost identical results. The ROC showed an 
AUC of 0.909. Only 16.7% of patients needed to be screened for a sensitivity of 95% and a 
specificity of 84.0% (details are presented in the supplemental material). 
 
Discussion 
This study investigated ways to improve ROP screening criteria in Switzerland. Based on the 
low prevalence of ROP therapy during a period of ten years of 1.2% in children born below 
32 weeks GA and less than 0.1% in infants born between 28 and 32 weeks, a logistic 
regression model was developed using known risk factors for ROP. The prediction model 
showed that all patients would have to be screened to guarantee a sensitivity of 100%. 
However, only 13% of patients needed to be screened for a sensitivity of 95.0%, missing one 
patient requiring ROP treatment. 
All screening programs aim for a high sensitivity, since no patients with the specific condition 
should be missed. This is particularly true for ROP, where an unidentified infant can suffer 
dramatic consequences such as severe visual impairment or even blindness, underlining the 
importance of achieving 100% sensitivity. On the other hand high sensitivity in turn leads to a 
low specificity. This exposes a high number of patients to minor consequences, which in ROP 
screening means exposure to pain, stress, increased work load and higher financial expenses. 
Therefore, screening criteria should identify patients at risk for ROP and limit screening to 
these patients as far as safely possible. Furthermore, the latest safe time to begin screening 
should be identified.  
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Screening criteria for ROP usually include birth weight and gestational age. In developed 
countries most recommendations state that patients with birth weight of less than 1250-1500g 
or a gestational age of less than 30-32 weeks should be screened for ROP(18).  
In developing countries recommendations frequently include patients with higher gestational 
age or higher birth weight (18). Several studies have shown that the incidence of ROP is 
higher in these countries and that application of criteria as defined by the American Academy 
of Pediatrics (AAP) (8) or the Royal College of Pediatrics and Child Health(19) misses 
patients needing ROP treatment (9, 10). This discrepancy confirms the absence of uniform 
screening criteria. Instead, we suggest that criteria could be improved if based on local risk 
factors and local incidence of ROP.  
 
Our prediction model including data imputation showed that only 13% of patients needed to 
be screened for ROP to reach a sensitivity of 95.0% missing one patient. This raises the 
question if there were additional risk factors in this patient and if this patient should have been 
screened for the above mentioned unclearly defined criteria. These criteria could not be 
included in the prediction model since databases rely on variables with clear definitions and 
therefore cannot include parameters such as “believed to be at risk”.  
The only patient missed with this prediction model suffered from a nephroblastoma. 
Nephroblastoma is a well vascularized tumor which is dependent on vasculogenesis for 
growth and which frequently expresses high doses of vascular growth factors, such as 
VEGF(20). It is well known, that VEGF plays a major role in the development of ROP in the 
second phase of relative hypoxia of the retina (2). Thus, it is very likely that the development 
of ROP in this patient was intensified by the growth factors produced by the tumor and not 
only by the usual pathophysiologic mechanisms occurring during ROP development in 
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preterm infants. Therefore, this patient had additional specific risk factors that make ROP 
screening necessary, independent of gestational age or birth weight.  
Altogether, these considerations indicate that there is a large potential to reduce ROP the 
indications for screening in Switzerland. Our model applies data available at patient discharge 
(duration of supplemental oxygen, CPAP and mechanical ventilation) and is therefore not fit 
for direct prospective implementation at screening age. To assess if a similar model can be 
achieved with variables that are available before first screening is performed, we included a 
second sensitivity analysis using modes of respiratory support as categorical variables. The 
results were almost identical to the first analysis, proving large potential to reduce ROP 
screening. However, a prospective study first needs to be performed based on these screening 
criteria and augmented by a list of diagnosis for which ROP screening should be performed 
(independent of gestational age or birth weight in very preterm infants). This should enable 
the selection of new screening criteria matching the local situation. 
 
Several studies assessed prediction models for ROP development. A recent publication 
summarized publications and methods which have been evaluated (21). Of these, the 
WINROP algorithm has been studied most extensively. WINROP was developed in Sweden 
and is based on postnatal weight gain, either alone (22) or in combination with serum levels of 
Insulin like growth factor 1 (IGF1) (23). The algorithm has mostly been tested retrospectively 
and was used in different populations. While prediction has shown to be excellent in one 
Swedish publication (24), application of the algorithm did not reach a sensitivity of 100% in 
all other populations with values mostly around 90% (25-28). Furthermore, these 
retrospective analyses included relatively small sample sizes of approximately 600 patients. 
This shows that a screening solely based on WINROP would fail to detect several patients 
developing severe ROP.  
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An extensive analysis of all Danish patients treated for ROP in the years 2002-2006 compared 
screening criteria combining gestational age at delivery and birth weight limits and new risk-
based criteria were compared with regards to their effectiveness (3). Results showed that a 
reduction of 17.4% of screened patients allowed the detection of all patients treated for ROP 
in the observation period and might lead to one missed treatment-demanding ROP every 11 
years and one case of blindness every 18 years. This implies that a potential for reduced ROP 
screening exists in Denmark. However, it also mirrors the difficulties of optimizing screening 
criteria with possibilities to avoid screening in a large group of preterm infants on the one 
hand but increasing risk to miss patients requiring ROP treatment on the other hand.  
 
Besides the question who needs to be screened for ROP it is also a matter of debate when 
screening should be started. The AAP recommends that the first ROP screening should be 
performed at a chronological age of 4 weeks but not before a postmenstrual age of 31 weeks 
is reached(8). These limits are considerably earlier than results of our study, where all patients 
would have been detected prior to therapy with limits of a chronological age of 60 days or 
postmenstrual age of 37 weeks. This shows that the development of ROP differs between 
populations not only concerning of incidence but also in terms chronologic progression. 
Starting ROP screening in Switzerland at a later chronologic and/or postmenstrual age than at 
the dates recommended by the AAP seems possible.  
 
Our study has several strengths and limitations. Of note is that different screening criteria 
were used across the neonatal centers, in particular some centers did not screen patients 
between 30 and 32 weeks GA. However, these units reduced screening because long periods 
of ROP-free infants above these criteria were documented. No extra cases of ROP were found 
at 2 years of age that were missed. Our study was based on a whole population in which a low 
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incidence of treated ROP was reported. This resulted in only 76 patients with treated ROP, 
which made the development, the validation of a prediction model and definition of new 
screening criteria difficult. Our precise data analyses revealed that results of this retrospective 
study are very robust and can therefore be expected to be valid. In order to further increase the 
validity of our results it would have been desirable to include more precise descriptions of 
ROP in terms of zone and plus disease stadium as well as type I and II ROP in the analyses 
(29). However, these data were not available from the SNN database.  
A strength of this study is the completeness of data. Almost 7000 preterm infants below 32 
weeks were evaluated over a period of 10 years. Concerning ROP, we reached data 
completeness of more than 97% of patients. The missing data was estimated using 
multivariate imputation by chained equations. Furthermore, and in contrast to many other 
databases the SNN database is not formed by a collaboration of certain hospitals, which might 
lead to a selection bias, but represents a whole population. Data of 96% of all Swiss VLBW 
infants born during the observation period were collected, making results representative for 
Switzerland. Gestational age stratified comparison with the birth registry of the federal 
statistical office revealed that the missing 4% of the population predominantly concern infants 
that died at extremely low gestational age in periphery low level neonatology units.  
 
Conclusion 
Results of this study show that it may be possible to greatly reduce the number of infants 
requiring ROP screening and thereby reducing their burden and saving health care costs and 
resources. A prospective test of the identified model is needed before it can be applied as a 
general guideline. 
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Figure legends 
 
 
Figure 1: Gestational age and Birth weight of the study population. Red dots show patients 
with treated ROP. 
 
Figure 2: ROC curve of c-statistic for prediction to need ROP treatment: AUC = 0.916  
 
 
 
Gestational age 
(weeks) 
23 24 25 26 27 28 29 30 31 Total 
n  
(%)  
19 
(0.3%) 
174 
(2.6%) 
334 
(5%) 
545 
(8.1%) 
661 
(9.8%) 
820 
(12.2%) 
1029 
(15.3%) 
1362 
(20.3%) 
1775 
(26.4%) 
6719 
(100%) 
Died >= 5 weeks GA 15.8% 4.6% 4.8% 2.2% 1.4% 1.0% 0.2% 0.5% 0.5% 1.1% 
Male sex 68.4% 50.6% 56.5% 51.4% 54.5% 51.6% 53.4% 55.2% 54.6% 53.9% 
Multiple births 47.4% 20.7% 21.3% 27.5% 28.0% 32.1% 36.3% 39.4% 37.9% 34.2% 
Antenatal steroids 84.2% 90.2% 93.4% 90.7% 90.4% 91.4% 93.0% 92.0% 89.6% 91.2% 
Caesarian section 52.6% 72.7% 79.0% 80.9% 79.3% 83.2% 80.7% 82.9% 78.0% 80.2% 
SGA 5.3% 7.5% 10.2% 9.0% 11.3% 8.7% 6.3% 7.4% 8.3% 8.3% 
Sepsis 26.3% 37.4% 29.0% 23.9% 17.1% 9.9% 7.3% 4.2% 3.3% 10.2% 
NEC 15.8% 9.2% 2.4% 3.3% 2.6% 2.6% 1.7% 1.5% 0.8% 2.0% 
Severe IVH 15.8% 9.8% 13.2% 7.0% 6.8% 2.9% 3.1% 2.6% 1.5% 3.9% 
O2 days 65.2 
(27.6) 
69.2 
(40.1) 
57 
(38.4) 
42.6 
(35.3) 
34.4 
(30.0) 
22.4 
(27.5) 
12.4 
(18.3) 
7.0  
(12.8) 
4.3 
(15.3) 
18.8 
(29.1) 
BPD 50.0% 45.5% 32.7% 23.8% 17.0% 10.9% 6.5% 3.6% 2.2% 10.0% 
Length of stay 
(days) 
126.6 
(67.4) 
120.8 
(39.9) 
110.3 
(38.2) 
95.5 
(31.3) 
85.7 
(27.1) 
73.8 
(30.8) 
62.2 
(22.9) 
51.5 
(20.3) 
42.6 
(17.6) 
65.4 
(33.6) 
ROP stage 0 62.5% 56.0% 61.5% 76.9% 86.3% 91.7% 95.5% 97.7% 98.6% 90.5% 
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ROP stage 1 31.2% 9.6% 12.6% 11.3% 8.7% 5.4% 2.6% 1.6% 1.1% 4.7% 
ROP stage 2 0.0% 13.9% 16.6% 7.2% 3.7% 2.2% 1.0% 0.5% 0.2% 2.9% 
ROP stage 3 6.2% 20.5% 9.2% 4.3% 1.2% 0.5% 0.7% 0.2% 0.1% 1.8% 
ROP stage 4 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 
ROP stage 5 0.0% 0.0% 0.0% 0.2% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 
Severe ROP 6.2% 20.5% 9.2% 4.5% 1.2% 0.8% 0.8% 0.2% 0.1% 1.9% 
ROP intervention 5.3% 14.5% 7.3% 2.6% 1.1% 0.5% 0.0% 0.2% 0.1% 1.2% 
ROP intervention 
anti-VEGF  
0.0% 0.6% 1.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 
ROP intervention 
lasertherapy  
5.3% 13.9% 6.1% 2.6% 1.1% 0.5% 0.0% 0.2% 0.1% 1.1% 
 
Table 1 Patient characteristics stratified by gestational age 
GA: gestational age; SGA: small for gestational age (<10th percentile) NEC: necrotizing enterocolitis; 
IVH: intraventricular hemorrhage; BPD: bronchopulmonary dysplasia; ROP retinopathy of 
prematurity 
 
GA Birth 
weight 
Birth 
weight  
z-score 
Gender Multiple 
birth 
Surfactant NEC IVH 
Grade 
Days 
O2 
Days 
CPAP 
Days mech. 
ventilation 
Days 
hospitalization 
GA at ROP 
treatment 
Birth defect 
27+0 1140g 0.576 M yes no no 0 72 32 0 82 42 2/7  
27+1 800g -0.908 M yes yes no 2 69 37 24 81 40 5/7  
27+1 700g -1.073 F yes yes no 3 68 39 5 81 38 5/7  
27+1 480g -2.306 M no yes yes 0 62 55 1 113 38 3/7  
27+2 960g 0.109 F no no no 0 12 33 0 62 38 2/7  
27+4 462g -2.155 F no no no 0 102 69 11 102 n/a  
28+0 770g -1.345 M no no no 2 111 37 0 116 36 4/7  
28+1 517g -2.034 F yes yes no 2 180 70 38 186 37 2/7  
28+3 680g -1.412 F no no no 0 52 39 2 84 37 5/7  
28+4 660g -1.489 F yes no no 0 124 69 17 215 40 0/7 Aortic coarctartion 
30+1 1530g 0.503 F no yes no 0 10 0 10 52 38 4/7 Mesoblastic nephroma 
30+5 1370g 0.006 F no yes no 0 36 9 5 72 37 3/7  
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31+4 1300g -0.725 M no no no 0 1 0 0 48 n/a  
 
 
Table 2: Parameters of patients with a gestational age above 26 weeks needing ROP treatment 
GA: gestational age; UA pH: pH in umbilical artery; NEC: necrotizing enterocolitis; IVH: 
intraventricular hemorrhage 
 
 est SE p-value Odds 
ratios 
95% CI 
(Intercept) -1.257 0.653 0.054 NA NA 
GA (weeks/days) -0.75 0.109 0 0.472 0.38-0.59 
SGA (yes) 0.666 0.389 0.087 1.946 0.91-4.17 
Multiple birth (yes) 0.669 0.313 0.033 1.952 1.06-3.61 
Surfactant 
administration (yes) 
-0.725 0.336 0.031 0.484 0.25-0.94 
O2 (day) 0.013 0.003 0 1.013 1.01-1.02 
CPAP (day) 0.012 0.004 0.008 1.012 1.00-1.02 
Ventilation (day) 0.015 0.007 0.037 1.015 1.00-1.03 
 
Table 3: Patient characteristics used in the final prediction model 
est: maximum likelihood estimator used for each parameter to calculate probability using 
formula above (bk); SE: standard error; OR: odds ratio; lo 95 / hi 95: 95% confidence interval.  
 
 
 
 
 
 
 
 
 
 
©    2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
  
 
 
 
 
cutoff at 
predicted 
value 
n needed 
to test 
True Pos False Neg Sensitivity Specificity 
0.000 2108 20 0 1.000 0.000 
0.001 1452 19 1 0.950 0.314 
0.002 1102 19 1 0.950 0.481 
0.040 284 19 1 0.950 0.873 
0.041 278 19 1 0.950 0.876 
0.042 272 18 2 0.900 0.878 
0.045 261 18 2 0.900 0.884 
0.046 255 17 3 0.850 0.886 
0.054 234 17 3 0.850 0.896 
0.055 231 16 4 0.800 0.897 
0.068 184 16 4 0.800 0.920 
0.069 178 15 5 0.750 0.922 
0.071 177 15 5 0.750 0.922 
0.072 174 14 6 0.700 0.923 
0.073 171 13 7 0.650 0.924 
…      
 
Table 4: Cutoff values for predicted ROP intervention probability.  
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